Handheld ISFET Lab-on-Chip detection of YAP1 nucleic acid and AR-FL and AR-V7 mRNA from Liquid Biopsies for Prostate Cancer Prognosis DOI Creative Commons
Joseph Broomfield, Melpomeni Kalofonou, Costanza Gulli

et al.

Biosensors and Bioelectronics, Journal Year: 2025, Volume and Issue: unknown, P. 117407 - 117407

Published: April 1, 2025

Prostate cancer (PCa) is a highly prevalent disease, causing the second largest amount of male deaths worldwide. Currently, prostate specific antigen (PSA) test remains standard serum prognostic and diagnostic monitoring biomarker but it lacks specificity sensitivity. PSA testing can lead to invasive biopsies which result in under detection clinically significant disease potential overtreatment indolent disease. Promising circulating biomarkers could facilitate less more accurate tests, present challenges robust quantitation deployment clinical settings. This work presents YAP1 nucleic acid, androgen receptor (AR-FL) AR-V7 mRNA for PCa prognostics blood plasma from patients. Sensitive AR-FL extracted samples was achieved with reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay. Optimisation extraction methodologies reliable RT-LAMP RT-qPCR took place. Multiplex acid on an ISFET Lab-on-Chip platform readily bio-electronic signal taking place within 15 min. Detection also be simultaneously handheld device. Evaluation data indicated that presence RNA patients correlated advanced staging (p = 0.043) at diagnosis 0.035). The Point-of-Care prognostics.

Language: Английский

Handheld ISFET Lab-on-Chip detection of YAP1 nucleic acid and AR-FL and AR-V7 mRNA from Liquid Biopsies for Prostate Cancer Prognosis DOI Creative Commons
Joseph Broomfield, Melpomeni Kalofonou, Costanza Gulli

et al.

Biosensors and Bioelectronics, Journal Year: 2025, Volume and Issue: unknown, P. 117407 - 117407

Published: April 1, 2025

Prostate cancer (PCa) is a highly prevalent disease, causing the second largest amount of male deaths worldwide. Currently, prostate specific antigen (PSA) test remains standard serum prognostic and diagnostic monitoring biomarker but it lacks specificity sensitivity. PSA testing can lead to invasive biopsies which result in under detection clinically significant disease potential overtreatment indolent disease. Promising circulating biomarkers could facilitate less more accurate tests, present challenges robust quantitation deployment clinical settings. This work presents YAP1 nucleic acid, androgen receptor (AR-FL) AR-V7 mRNA for PCa prognostics blood plasma from patients. Sensitive AR-FL extracted samples was achieved with reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay. Optimisation extraction methodologies reliable RT-LAMP RT-qPCR took place. Multiplex acid on an ISFET Lab-on-Chip platform readily bio-electronic signal taking place within 15 min. Detection also be simultaneously handheld device. Evaluation data indicated that presence RNA patients correlated advanced staging (p = 0.043) at diagnosis 0.035). The Point-of-Care prognostics.

Language: Английский

Citations

0